Long-term air humidification therapy is cost-effective for patients with moderate or severe chronic obstructive pulmonary disease or bronchiectasis

Value in Health

Volumn 17, Issue 4, 2014, Pages 320-327

  Milne, Richard J ^a   Hockey, Hans ^b   Rea, Harry ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Biometrics Matters Limited   (United States)

Author keywords

air humidification; bronchiectasis; COPD; cost effectiveness; economic evaluation

Indexed keywords

ANTIBIOTIC AGENT; PREDNISONE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ASTHMA; BRONCHIECTASIS; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSULTATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSIS RELATED GROUP; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; ECONOMIC EVALUATION; EMERGENCY CARE; EMERGENCY PHYSICIAN; EMERGENCY WARD; FEMALE; FUNDING; HAEMOPHILUS INFLUENZAE; HEALTH STATUS; HEMOPTYSIS; HOSPITAL ADMISSION; HUMAN; ICD-10; LONG TERM AIR HUMIDIFICATION THERAPY; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEW ZEALAND; OUTCOME ASSESSMENT; OXYGEN THERAPY; PATIENT CARE; PNEUMONIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; RESPIRATORY GAS HUMIDIFIER; ST. GEORGE RESPIRATORY QUESTIONNAIRE; UPPER RESPIRATORY TRACT INFECTION;

AIR HUMIDIFICATION; BRONCHIECTASIS; COPD; COST-EFFECTIVENESS; ECONOMIC EVALUATION;

AGED; BRONCHIECTASIS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HUMIDITY; MALE; NEW ZEALAND; OXYGEN INHALATION THERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84903172472     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2014.01.007     Document Type: Article

References (51)

1. Global Initiative for Chronic Obstructive Lung Disease Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2011. Available from: http://www.goldcopd.org. [Accessed April 11, 2014].
2. World Health Organization. Chronic obstructive pulmonary disease (COPD). 2004. Available from: www.who.int/respiratory/copd/en/index.html. [Accessed March 31, 2014].
3. H.J. Starkie, A.H. Briggs, and M.G. Chambers Pharmacoeconomics in COPD: lessons for the future Int J Chron Obstruct Pulmon Dis 3 2008 71 88
4. M.C. Pasteur, D. Bilton, A.T. Hill British Thoracic Society Bronchiectasis non-CF Guideline Group British Thoracic Society guideline for non-CF bronchiectasis Thorax 65 Suppl. 1 2010 i1 58
5. Asia Pacific COPD Roundtable Group Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective Respirology 10 1 2005 9 17
6. P. Shirtcliffe, M. Weatherall, and S. Marsh et al. COPD prevalence in a random population survey: a matter of definition Eur Respir J 30 2007 232 239
7. M.E. Roberts, L. Lowndes, D.G. Milne, and C.A. Wong Socioeconomic deprivation, readmissions, mortality and acute exacerbations of bronchiectasis Intern Med J 42 2012 e129 e136
8. L.B. Gerald, and W.C. Bailey Global initiative for chronic obstructive lung disease J Cardiopulm Rehabil 22 2002 234 244
9. D.K. McKenzie, P.A. Frith, and J.G.W. Burdon et al. The COPDX Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2003 Med J Aust 178 Suppl. 2003 S7 39
10. P.W. Jones, F.H. Quirk, and C.M. Baveystock The St George's Respiratory Questionnaire Respir Med 85 Suppl. B 1991 25 31 (discussion 3-7)
11. C.B. Wilson, P.W. Jones, and C.J. O'Leary et al. Validation of the St. George's Respiratory Questionnaire in bronchiectasis Am J Respir Crit Care Med 156 2, Pt 1 1997 536 541
12. H. Rea, S. McAuley, and L. Jayaram et al. The clinical utility of long-term humidification therapy in chronic airway disease Respir Med 104 2010 525 533
13. A. Hasani, T.H. Chapman, and D. McCool et al. Domiciliary humidification improves lung mucociliary clearance in patients with bronchiectasis Chron 5 2008 81 86
14. PHARMAC Prescription for Pharmacoeconomic Analysis, Version 2.1 2012 PHARMAC Wellington, New Zealand
15. Drummond M, O'Brien B, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes (2nd ed.). New York, NY: Oxford Medical Publications, 1997.
16. Metcalfe S, Grocott R. Comments on "Simoens, S. Health economic assessment: a methodological primer." Int J Environ Res Public Health 2010;7:1831-4.
17. PHARMAC. New Zealand pharmaceutical schedule. 2012. Available from: http://www.pharmac.govt.nz/Schedule. [Accessed March 31, 2014].
18. PHARMAC. Resource manual. 2012. Available from: http://www.pharmac.govt. nz/?q=resource+manual. [Accessed March 31, 2014].
19. H.J. Starkie, A.H. Briggs, M.G. Chambers, and P. Jones Predicting EQ-5D values using the SGRQ Value Health 14 2011 354 360
20. G. Samsa, D. Edelman, and M.L. Rothman et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II Pharmacoeconomics 15 1999 141 155
21. A. Briggs, and P. Fenn Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane Health Econ 7 1998 723 740
22. R.M. Nixon, D. Wonderling, and R.D. Grieve Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared Health Econ 19 2010 316 333
23. M.J. Al Cost-effectiveness acceptability curves revisited Pharmacoeconomics 31 2013 93 100
24. MRC. Bootstrap spreadsheet. 2005. Available from: http://mrcblogs. helpfulclients.com/bsu/software/software-downloads/. [Accessed March 31, 2014].
25. G.C. Donaldson, J.R. Hurst, and C.J. Smith et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD Chest 137 2010 1091 1097
26. T. Simon-Tuval, S.M. Scharf, and N. Maimon et al. Determinants of elevated healthcare utilization in patients with COPD Respir Res 12 2011 7
27. A.A. Dalal, L. Christensen, F. Liu, and A.A. Riedel Direct costs of chronic obstructive pulmonary disease among managed care patients Int J Chron Obstruct Pulmon Dis 5 2010 341 349
28. D.W. Mapel, M. Schum, E. Lydick, and J.P. Marton A new method for examining the cost savings of reducing COPD exacerbations Pharmacoeconomics 28 2010 733 749
29. K.-H. Lee, J. Phua, and T.-K. Lim Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore Respir Med 100 2006 2190 2196
30. C. Esteban, J.M. Quintana, and J. Moraza et al. Impact of hospitalisations for exacerbations of COPD on health-related quality of life Respir Med 103 2009 1201 1208
31. W. Vincken, J.A. van Noord, and A.P.M. Greefhorst et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium Eur Respir J 19 2002 209 216
32. P.M.A. Calverley, J.A. Anderson, and B. Celli et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [Reprint in Ugeskr Laeger 2007;169:3198-201] N Engl J Med 356 2007 775 789
33. M.A. Martinez-Garcia, M. Perpina-Tordera, P. Roman-Sanchez, and J.J. Soler-Cataluna Quality-of-life determinants in patients with clinically stable bronchiectasis Chest 128 2005 739 745
34. D.P. Tashkin, B. Celli, and S. Senn et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
35. D.P. Tashkin, B. Celli, and S. Kesten et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial [Erratum appears in Eur Respir J 2010;35:1195] Eur Respir J 35 2010 287 294
36. T. Ringbaek, E. Brondum, G. Martinez, and P. Lange EuroQoL in assessment of the effect of pulmonary rehabilitation COPD patients Respir Med 102 2008 1563 1567
37. T. Ringbaek, G. Martinez, and P. Lange A comparison of the assessment of quality of life with CAT, CCQ, and SGRQ in COPD patients participating in pulmonary rehabilitation COPD 9 2012 12 15
38. Rutten-van Molken MPMH, J.B. Oostenbrink, and D.P. Tashkin et al. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 130 2006 1117 1128
39. R. Hettle, H. Wouters, and J. Ayres et al. Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium Respir Med 106 2012 1722 1733
40. N.J. Devlin, P. Hansen, P. Kind, and A. Williams Logical inconsistencies in survey respondents' health state valuations - a methodological challenge for estimating social tariffs Health Econ 12 2003 529 544
41. J. Petrillo, F. van Nooten, and P. Jones et al. Utility estimation in chronic obstructive pulmonary disease: a preference for change? Pharmacoeconomics 29 2011 917 932
42. A.H. Briggs, H.A. Glick, and G. Lozano-Ortega et al. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study Eur Respir J 35 2010 532 539
43. S.J. Walters, and J.E. Brazier Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D Qual Life Res 14 2005 1523 1532
44. N. Hertel, R.W. Kotchie, and Y. Samyshkin et al. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis Int J Chron Obstruct Pulmon Dis 7 2012 183 199
45. MPMH Rutten-van Molken, and L.M.A. Goossens Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues Pharmacoeconomics 30 2012 271 302
46. PHARMAC. Decision criteria. 2011. Available from: http://www.pharmac. govt.nz/suppliers/DecisionMakingProcess/DecisionCriteria. [Accessed March 31, 2014].
47. S. Metcalfe, A. Rodgers, R. Werner, and C. Schousboe PHARMAC has no cost-effectiveness threshold N Z Med J 125 2012 99 101
48. Organisation for Economic Co-operation and Development. Purchasing power parity. 2012. Available from: http://stats.oecd.org/Index.aspx?datasetcode=SNA- TABLE4. [Accessed March 31, 2014].
49. N. Devlin, and D. Parkin Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis Health Econ 13 2004 437 452
50. K. Shah, C. Praet, and N. Devlin et al. Is the aim of the English health care system to maximize QALYs? J Health Serv Res Policy 17 2012 157 163
51. C. McCabe, K. Claxton, and A.J. Culyer The NICE cost-effectiveness threshold: what it is and what that means Pharmacoeconomics 26 2008 733 744